축성 척추 관절염 치료 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측, 치료법별, 적응증별, 최종 사용자별, 기업별, 지역별 분석(2017-2027년)
Axial Spondyloarthritis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Therapy, By Indication, By End User, By Company, and By Region
세계 축성 척추 관절염 치료제 시장은 예측 기간인 2023년부터 2027년까지 괄목할 만한 성장을 보일 것으로 예상됩니다.
축성 척추 관절염의 발병률 증가와 이 질환에 대한 사회적 인식이 높아지면서 축성 척추 관절염 시장의 성장을 가속하는 주요 요인으로 작용하고 있습니다. 축성 척추 관절염은 축성 골격에 영향을 미치는 만성 염증성 질환입니다. 축성 척추 관절염은 축성 골격에 영향을 미치는 만성 염증성 질환으로 극심한 불편감, 허리 뻣뻣함, 피로감 등을 유발하는 질환입니다. 기타 시장 개척 요인으로는 세계 인구 증가, 연구 활동 증가, 환자 수 급증, 수많은 임상시험, 제품 혁신 및 개발 증가, R&D에 대한 막대한 투자, 1인당 의료비 증가, 축성 척추 관절염 유병률 증가, M&A 증가, 기존 의료 인프라 개선에 대한 여러 당국의 강조 등이 있습니다.의 강조를 들 수 있습니다.
축성 척추 관절염 발병 급증
축성 척추 관절염의 유병률이 세계적으로 증가하면서 시장 성장을 견인하고 있습니다. 축성 척추관절염의 원인은 불분명하지만, 여러 연구 결과에 따르면 유전자가 특정 박테리아, 바이러스 또는 기타 유발 요인에 노출되어 발생하는 것으로 추정됩니다. 환자들은 환부의 뻣뻣함과 피로감 등 심각한 불편함을 겪게 됩니다. 또한 노인뿐만 아니라 젊은 세대도 발병하기 쉬운 질병입니다. 이러한 요인들이 세계 시장 성장을 견인하고 있습니다. 미국에서는 약 270만 명 이상의 미국인이 축성 척추 관절염(axSpA)을 앓고 있다는 조사 결과도 있습니다.
승인된 바이오시밀러 의약품 증가
세계보건기구(WHO)에 따르면, 바이오시밀러는 이미 허가된 오리지널 바이오의약품과 안전성, 품질, 유효성 측면에서 유사한 바이오의약품을 말합니다. 바이오시밀러는 축성 척추관절염 등의 치료에 도움이 되는 생물학적 제제입니다. 환자들에게 매우 효과적이며, 쉽게 구할 수 있다는 장점으로 인해 오리지널 의약품을 대체하고 있습니다. 지난 몇 년동안 축성 척추 관절염 치료제로 승인된 바이오시밀러의 수가 급증하고 있으며, 이는 세계 시장 성장을 견인하고 있습니다. 예를 들어, 2020년과 2021년 미국 식품의약국(FDA)은 축성 척추관절염 환자 치료를 위한 세 가지 새로운 제품, 즉 Xeljanz, Taltz, Cosentyx를 승인했습니다.
연구개발 활동의 활성화
분자생물학 및 면역학 분야의 연구개발 활동이 활발해지면서 시장 성장을 견인하고 있습니다. 연구 활동 증가로 종양괴사인자(TNF) 억제제, IL-23, 인터루킨(IL)-17 억제제와 같은 새로운 생물학적 제제의 출현이 급증하고 있습니다. 예를 들어, 2022년 세계 바이오제약 기업 UCB는 BE MOBILE 1 임상 3상 시험이 주요 평가항목과 순위가 매겨진 모든 부수적 평가항목을 달성했다는 중간 분석 결과를 발표했습니다. axSpA)를 앓고 있는 성인을 대상으로 비멕시주맙의 유효성과 안전성을 측정하는 주요 임상입니다. 또한, 정부의 연구 활동에 대한 투자 증가는 시장 성장을 가속하는 요인으로 작용하고 있습니다.
사용자 지정 가능
TechSci Research는 주어진 시장 데이터를 기반으로 기업의 특정 요구에 따라 맞춤화를 제공합니다. 본 보고서에서는 다음과 같은 커스터마이징이 가능합니다.
기업 소개
- 추가 시장 기업에 대한 상세한 분석 및 프로파일링(최대 5개사).
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 세계 축성 척추 관절염 치료 시장에 대한 COVID-19의 영향
제5장 고객의 소리(VOC )
제6장 임상시험 분석
제7장 세계의 축성 척추 관절염 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 치료법별(Anti-Tumor Necrosis Factor (TNF) Therapy, Anti-Interleukin (IL) Therapy, Anti-Janus Kinase (JAK) Therapy)
- 적응증별(강직성 척추염/비방사선성 축성 척추 관절염 치료)
- 최종사용자별(병원 및 진료소, 학술 및 연구기관, 기타)
- 지역별
- 기업별(2021년)
- 시장 맵
제8장 북미의 축성 척추 관절염 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 북미 국가별 분석
제9장 유럽의 축성 척추 관절염 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 유럽 국가별 분석
제10장 아시아태평양의 축성 척추 관절염 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 아시아태평양 국가별 분석
제11장 남미의 축성 척추 관절염 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 남미 국가별 분석
제12장 중동 및 아프리카의 축성 척추 관절염 치료 시장 전망
- 시장 규모와 예측
- 시장 점유율과 예측
- 중동 및 아프리카(MEA) 국가별 분석
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
제13장 시장 역학
제14장 시장 동향과 개척
제15장 경쟁 구도(종합적 SWOT 분석)
- Novartis International, AG
- Eli Lilly and Company
- Johnson & Johnson
- UCB S.A.
- Pfizer, Inc.
- Kyowa Kirin Co., Ltd.
- Merck & Co., Inc.
- AbbVie Inc
- Bristol-Myers Squibb Company
- FunPep Co., Ltd.
제16장 전략적 제안
LSH
The global axial spondyloarthritis treatment market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors, including the rising incidence of axial spondyloarthritis and increasing public awareness of the disease, are propelling the growth of the market. Axial spondyloarthritis is a chronic inflammatory condition that impacts the axial skeleton. The person undergoes severe discomfort, stiffness in the back area, and fatigue because of it. The other factors supporting the market's growth are the growing world population, increasing research activities, a surge in the number of patients, a large number of clinical trials, rising product innovation and development, significant investment in research and development, rising per capita health care expenditure, increasing prevalence of axial spondyloarthritis, growing number of mergers and acquisitions, and rising emphasis of several authorities on improving existing healthcare infrastructure.
A surge in Incidences of Axial Spondylarthritis
The increasing prevalence of axial spondylarthritis across the globe is bolstering the growth of the market. The cause of axial spondylarthritis is not known, but after several research, it is assumed that it is caused due to the exposure of genes to certain bacteria, viruses, or other triggers. Patients undergo serious discomforts, such as stiffness in the affected part and fatigue. Not only the elderly population but the younger generation are also prone to the disease. Therefore, these factors are bolstering the growth of the market globally. According to a cited study, in the U.S., about 2.7 million Americans or more are affected by axial spondyloarthritis (axSpA).
Increase in the Number of Approved Biosimilars
According to the World Health Organization (WHO), Biosimilars refer to a biotherapeutic product that is similar in terms of safety, quality, and efficacy to an already licensed original biotherapeutic product. Biosimilars are biological drugs that help in treating diseases such as axial spondylarthritis. They are very effective in patients and have replaced originator drugs due to their greater accessibility. In the past few years, there has been a surge in the number of approved biosimilars for the treatment of axial spondylarthritis, which is augmenting the growth of the market globally. For instance, in 2020 and 2021, the U.S. Food and Drug Administration approved three novel products, i.e., Xeljanz, Taltz, and Cosentyx, to treat individuals with axial spondyloarthritis.
Increasing R&D Activities
Rise in research and development (R&D) activities in the molecular and immunologic field are propelling the growth of the market. Owing to the increase in research activities, the advent of novel biologic agents such as tumor necrosis factor (TNF) inhibitors, IL-23, and interleukin (IL)-17 inhibitors are surging. For instance, in 2022, UCB, a global biopharmaceutical company, announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study met the primary and all ranked secondary endpoints. BE MOBILE 1 is the primary study to measure the effectiveness and safety of bimekizumab in adults suffering from active non-radiographic axial spondyloarthritis (nr-axSpA). Moreover, the rising investments in the research activities by the government are facilitating the growth of the market.
Market Segmentation
The global axial spondyloarthritis treatment market is segmented into therapy, indication, end user, and company. Based on therapy, the market is divided into anti-tumor necrosis factor (TNF) therapy, anti-interleukin (IL) therapy, and anti-Janus kinase (JAK) therapy. Based on indication, the market is divided into ankylosing spondylitis and non-radiographic axial spondyloarthritis treatment. Based on end-user, the market is divided into hospitals & clinics, academic & research institutions, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rise in R&D activities in the country.
Market Players
Novartis International, AG, Eli Lilly and Company, Johnson & Johnson, UCB S.A., Pfizer, Inc., Kyowa Kirin Co., Ltd., Merck & Co., Inc., AbbVie Inc, Bristol-Myers Squibb Company, and FunPep Co., Ltd. are some of the leading companies operating in the market.
Report Scope
In this report, global axial spondyloarthritis treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Axial Spondyloarthritis Treatment Market, By Therapy:
- Anti-Tumor Necrosis Factor (TNF) Therapy
- Anti-Interleukin (IL) Therapy
- Anti-Janus Kinase (JAK) Therapy
Axial Spondyloarthritis Treatment Market, By Indication:
- Ankylosing Spondylitis
- Non-radiographic Axial Spondyloarthritis Treatment
Axial Spondyloarthritis Treatment Market, By End User:
- Hospitals & Clinics
- Academic & Research Institutions
- Others
Axial Spondyloarthritis Treatment Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Europe & CIS
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in Global Axial Spondyloarthritis Treatment Market
Available Customizations
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
2. Research Methodology
3. Executive Summary
4. Impact of COVID-19 on Global Axial Spondyloarthritis Treatment Market
5. Voice of Customer
6. Clinical Trial Analysis
7. Global Axial Spondyloarthritis Treatment Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Therapy (Anti-Tumor Necrosis Factor (TNF) Therapy, Anti-Interleukin (IL) Therapy, Anti-Janus Kinase (JAK) Therapy)
- 7.2.2. By Indication (Ankylosing Spondylitis v/s Non-radiographic Axial Spondyloarthritis Treatment)
- 7.2.3. By End User (Hospitals & Clinics, Academic & Research Institutions, Others)
- 7.2.4. By Region
- 7.2.5. By Company (2021)
- 7.3. Market Map
8. North America Axial Spondyloarthritis Treatment Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Therapy
- 8.2.2. By Indication
- 8.2.3. By End User
- 8.2.4. By Country
- 8.3. North America: Country Analysis
- 8.3.1. United States Axial Spondyloarthritis Treatment Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Therapy
- 8.3.1.2.2. By Indication
- 8.3.1.2.3. By End User
- 8.3.2. Canada Axial Spondyloarthritis Treatment Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Therapy
- 8.3.2.2.2. By Indication
- 8.3.2.2.3. By End User
- 8.3.3. Mexico Axial Spondyloarthritis Treatment Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Therapy
- 8.3.3.2.2. By Indication
- 8.3.3.2.3. By End User
9. Europe Axial Spondyloarthritis Treatment Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Therapy
- 9.2.2. By Indication
- 9.2.3. By End User
- 9.2.4. By Country
- 9.3. Europe: Country Analysis
- 9.3.1. France Axial Spondyloarthritis Treatment Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Therapy
- 9.3.1.2.2. By Indication
- 9.3.1.2.3. By End User
- 9.3.2. Germany Axial Spondyloarthritis Treatment Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Therapy
- 9.3.2.2.2. By Indication
- 9.3.2.2.3. By End User
- 9.3.3. United Kingdom Axial Spondyloarthritis Treatment Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Therapy
- 9.3.3.2.2. By Indication
- 9.3.3.2.3. By End User
- 9.3.4. Italy Axial Spondyloarthritis Treatment Market Outlook
- 9.3.4.1. Market Size & Forecast
- 9.3.4.2. Market Share & Forecast
- 9.3.4.2.1. By Therapy
- 9.3.4.2.2. By Indication
- 9.3.4.2.3. By End User
- 9.3.5. Spain Axial Spondyloarthritis Treatment Market Outlook
- 9.3.5.1. Market Size & Forecast
- 9.3.5.2. Market Share & Forecast
- 9.3.5.2.1. By Therapy
- 9.3.5.2.2. By Indication
- 9.3.5.2.3. By End User
10. Asia-Pacific Axial Spondyloarthritis Treatment Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Therapy
- 10.2.2. By Indication
- 10.2.3. By End User
- 10.2.4. By Country
- 10.3. Asia-Pacific: Country Analysis
- 10.3.1. China Axial Spondyloarthritis Treatment Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Therapy
- 10.3.1.2.2. By Indication
- 10.3.1.2.3. By End User
- 10.3.2. India Axial Spondyloarthritis Treatment Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Therapy
- 10.3.2.2.2. By Indication
- 10.3.2.2.3. By End User
- 10.3.3. Japan Axial Spondyloarthritis Treatment Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Therapy
- 10.3.3.2.2. By Indication
- 10.3.3.2.3. By End User
- 10.3.4. South Korea Axial Spondyloarthritis Treatment Market Outlook
- 10.3.4.1. Market Size & Forecast
- 10.3.4.2. Market Share & Forecast
- 10.3.4.2.1. By Therapy
- 10.3.4.2.2. By Indication
- 10.3.4.2.3. By End User
- 10.3.5. Australia Axial Spondyloarthritis Treatment Market Outlook
- 10.3.5.1. Market Size & Forecast
- 10.3.5.2. Market Share & Forecast
- 10.3.5.2.1. By Therapy
- 10.3.5.2.2. By Indication
- 10.3.5.2.3. By End User
11. South America Axial Spondyloarthritis Treatment Market Outlook
- 11.1. Market Size & Forecast
- 11.2. Market Share & Forecast
- 11.2.1. By Therapy
- 11.2.2. By Indication
- 11.2.3. By End User
- 11.2.4. By Country
- 11.3. South America: Country Analysis
- 11.3.1. Brazil Axial Spondyloarthritis Treatment Market Outlook
- 11.3.1.1. Market Size & Forecast
- 11.3.1.2. Market Share & Forecast
- 11.3.1.2.1. By Therapy
- 11.3.1.2.2. By Indication
- 11.3.1.2.3. By End User
- 11.3.2. Argentina Axial Spondyloarthritis Treatment Market Outlook
- 11.3.2.1. Market Size & Forecast
- 11.3.2.2. Market Share & Forecast
- 11.3.2.2.1. By Therapy
- 11.3.2.2.2. By Indication
- 11.3.2.2.3. By End User
- 11.3.3. Colombia Axial Spondyloarthritis Treatment Market Outlook
- 11.3.3.1. Market Size & Forecast
- 11.3.3.2. Market Share & Forecast
- 11.3.3.2.1. By Therapy
- 11.3.3.2.2. By Indication
- 11.3.3.2.3. By End User
12. Middle East and Africa Axial Spondyloarthritis Treatment Market Outlook
- 12.1. Market Size & Forecast
- 12.2. Market Share & Forecast
- 12.2.1. By Therapy
- 12.2.2. By Indication
- 12.2.3. By End User
- 12.2.4. By Country
- 12.3. MEA: Country Analysis
- 12.3.1. South Africa Axial Spondyloarthritis Treatment Market Outlook
- 12.3.1.1. Market Size & Forecast
- 12.3.1.2. Market Share & Forecast
- 12.3.1.2.1. By Therapy
- 12.3.1.2.2. By Indication
- 12.3.1.2.3. By End User
- 12.3.2. Saudi Arabia Axial Spondyloarthritis Treatment Market Outlook
- 12.3.2.1. Market Size & Forecast
- 12.3.2.2. Market Share & Forecast
- 12.3.2.2.1. By Therapy
- 12.3.2.2.2. By Indication
- 12.3.2.2.3. By End User
- 12.3.3. UAE Axial Spondyloarthritis Treatment Market Outlook
- 12.3.3.1. Market Size & Forecast
- 12.3.3.2. Market Share & Forecast
- 12.3.3.2.1. By Therapy
- 12.3.3.2.2. By Indication
- 12.3.3.2.3. By End User
13. Market Dynamics
- 13.1. Drivers
- 13.2. Challenges
14. Market Trends & Developments
15. Competitive Landscape (Inclusive SWOT Analysis)
- 15.1. Novartis International, AG
- 15.2. Eli Lilly and Company
- 15.3. Johnson & Johnson
- 15.4. UCB S.A.
- 15.5. Pfizer, Inc.
- 15.6. Kyowa Kirin Co., Ltd.
- 15.7. Merck & Co., Inc.
- 15.8. AbbVie Inc
- 15.9. Bristol-Myers Squibb Company
- 15.10. FunPep Co., Ltd.
16. Strategic Recommendations
